Skip to main content

Market Overview

AstraZeneca, Junshi Bio In Commercialization Pact For Toripalimab In China


AstraZeneca Plc (NASDAQ: AZN) has announced a deal with Shanghai Junshi Biosciences Co Ltd to market Junshi’s cancer drug.

  • Under the agreement, AstraZeneca will be granted the right to market Junshi’s anti-PD-1 cancer drug toripalimab for urothelial carcinoma across China and other cancer types in some areas.
  • Both the companies will also discuss commercial cooperation in emerging markets.
  • Toripalimab belongs to PD-1 or PD-L1 that utilizes a patient’s immune system to fight cancer. 
  • Price Action: AZN shares are up 0.8% at $48.78 in premarket trading on the last check Monday.

Related Articles (AZN)

View Comments and Join the Discussion!

Posted-In: Urothelial CancerBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at